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Abstract
Objective: Schizophrenia, a neuropsychiatric disorder, is known to be neurodevelopmentally progressive. 
Due to the extensive interindividual variability found in the responses of patients, management of schizophrenia 
has proven to be challenging. This interindividual variability to treatment could be justified by the variation of the 
enzymes in charge of metabolizing medications, especially those associated with cytochrome P450. Since genetic 
factors influence the phenotypic responses to drugs, researchers are involved in identifying schizophrenic genetic 
factors, which could impact responses and severe effects for commonly known neuroleptic drugs known as 
pharmacogenetics. In order to predict drug response at the personal level, genetic variants that determine drug 
effects need to be identified. 
Methods: We have chosen to investigate gene targets for risperidone and clozapine, two commonly administered 
drugs for the treatment of schizophrenia. The aim of this review is to contribute in the understanding of genetic 
influences on drug responses of risperidone and clozapine in schizophrenia. We reviewed original primary research 
articles, meta-analysis, and review publications on drug and gene interaction on the treatment of schizophrenia. Our 
main findings focused on schizophrenia, pharmacogenetics and cytochrome P450. 
Results and conclusion: After filtering our results to human species and English language, a total of 45 
scientific articles were used for this review. A promising direction for future research in schizophrenia treatment lies 
behind the identification of the specific genetic contributors that affect drug response. 
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The debilitating disease schizophrenia, which affects millions 
of people, is a chronic, neuropsychiatric disorder, considered 
neurodevelopmentally progressive, and ranks as one of the 20 major 
factors for disability in the world [1,2]. Schizophrenia is also considered 
a complex disorder that cannot be described as a single developmental, 
degenerative process because of how challenging it is to be diagnosed 
and treated [1,3]. Statistically, individuals with one immediate family 
member affected with the disease are usually 10 times more prone to be 
affected with schizophrenia, while individuals with both parents affected 
with the disease are around 50 times more likely to also be affected [4]. 
Moreover, unlike the plaques and tangles that characterize Alzheimer’s 
disease, the brain abnormalities found in schizophrenic patients do not 
usually contribute to a diagnosis [4]. Today, schizophrenia is usually 
treated with antipsychotic medications either first generation, also 
known as typical, or second generation, known as atypical. Although, 
both categories block dopamine receptors, the second generation drugs 
also affect serotonin levels. The use of these medications could result 
in increased morbidity, which includes extrapyramidal-like symptoms, 
weight gain, and rigidity [5]. Typical antipsychotics generally treat 
positive symptoms associated with schizophrenia but these types of 
medications are also found to cause unwelcome motor side effects. In 
comparison, atypical antipsychotics have the ability to effectively treat 
both positive and negative symptoms associated with schizophrenia, 
but may also lead to severe metabolic side effects [6]. Despite the large 
availability of resources in the medical field, physicians still struggle to 
produce rational treatment options. Consequently, the trial and error 
method is utilized and usually results in patient suffering, high cost, and 
stress on the patient and the patient’s family [7]. Previously, a traditional 
approach has been used in order to develop drug compounds that 
exhibit a mean average response from the population, which usually 
results in large interindividual variation in the way that patients 
respond to specific drugs [7]. 
Cytochrome p450 (CYP)
Due to the extensive interindividual variability found in the 
responses of patients, management of schizophrenia has proven to 
be challenging [3]. This interindividual variability to treatment could 
possibly be justified by the variation of the enzymes in charge of 
metabolizing medications, especially the enzyme system associated with 
cytochrome P450 (CYP), which is composed of the major enzymes in 
charge of the entire metabolic process [3,8,9]. This system is made up of 
a family of isoenzymes, which are located in the inner membrane of the 
mitochondria or the smooth endoplasmic reticulum of cells, especially 
in the liver [10]. The major enzymes that have been identified from 
the CYP family include CYP1A2, CYP2D6, CYP3A4 and CYP2C19. 
These enzymes are coded by highly polymorphic genes [11]. For 
instance, CYP2D6 contains over 60 alleles and 130 genetic variations 
due to combinations of single nucleotide polymorphisms (SNPs) and 
Citation: Cho M, Contreras A, Garza A, Olvera S, Castillo D, et al. (2017) The Impact of Drug and Gene Interaction on the Antipsychotic Medication 
for Schizophrenia. Bipolar Disord 3: 117. doi: 10.4172/2472-1077.1000117
Page 2 of 7
Volume 3 • Issue 1 • 1000117
Bipolar Disord, an open access journal 
ISSN: 2472-1077
copy number variations. This gene is found to be highly polymorphic. 
CYP2D6, along with the other variants of the CYP family, metabolize 
different types of antipsychotics [12]. Moreover, out of five main 
CYP genes, the function of CYP2D6 is to metabolize several existing 
prescribed antipsychotics as well as antidepressants and anxiolytics. The 
CYP2D6 is one of the major genes in drug metabolism and it is located 
on chromosome 22 [6]. Many antipsychotic drugs are considered 
lipophilic compounds and require extensive metabolic energy in 
order to be excreted from the body [13]. Approximately 20-25% of 
clinically used medications are metabolized by the enzyme CYP2D6 
[14]. Furthermore, a genetic impairment in CYP2D6 contributes to the 
development of extrapyramidal side-effects, which usually result from 
long-term schizophrenic treatment [12]. Additionally, the amount of 
drug concentration is based on the rate at which enzymes metabolize 
it, which is affected by genetic polymorphisms. Consequently, lower 
rates of enzymatic activity will likely result in higher concentrations of 
the drug and the possibility of adverse drug responses, while a higher 
rate of enzymatic activity can result in a decrease of plasma levels and 
diminished drug effects [6].
Pharmacogenetics
Since genetic factors influence the phenotypic responses to drugs, 
an increasing number of researchers are involved in identifying 
schizophrenic genetic factors for the disorder and treatment responses 
for commonly known neuroleptic drugs [15,16]. This is where the field of 
pharmacogenetics plays a major role. Pharmacogenetics focuses on the 
relationship between the pharmacokinetic level or the pharmacodynamic 
level and interindividual differences [15]. The pharmacokinetics focuses 
on the way drugs being metabolized based on individual genetic 
differences, while pharmacodynamics is to elucidate the differences in 
responses among individuals [15]. Pharmacogenetics also focuses on 
variations found in the human genome and in the different ways in which 
individuals respond to drugs based on genetic factors [17]. Despite the 
fact that there is a large variety of available medications, as many as 30-
50% of the patients with treatment of antidepressants and antipsychotics 
will not adequately respond to treatment [16]. In order to predict drug 
response at the personal level, genetic variants that determine drug effects 
need to be identified [15]. Therefore, pharmacogenetics is to understand 
individual differences within humans to help identify potential variants 
in order to help formulate an individualized care for patients using 
antipsychotic medications [8]. Recent scientific advancements, such 
as the Human Genome Project, cutting edge technology and methods 
of DNA analysis progress, have introduced new tools that aid in the 
identification of genetic variation focusing on a drug target level. Giving 
a new perspective for the field of pharmacogenetics [15], a large number 
of research studies has been conducted. Although a vast amount of 
genetic variation has been depicted regarding responses to certain 
pharmaceutical medications, genetic tools are not able to identify the 
likelihood of an individualized response to treatment. Consequently, 
there is difficulty in establishing personalized drug therapies with 
favorable options regarding medication and dosage. Despite the 
development of expedient and more effective methods in genetic testing, 
clinical application in the use of pharmacogenetics as a guide for therapy 
may only be possible through the availability of a reliable predictor for 
clinical outcomes [16].
Drugs 
In order to appropriately select genes to investigate, familiarity with 
a specific drug's mechanism of action must be known. Consequently, 
there is an inclination to study well known drug targets [7]. Therefore, 
we have chosen to investigate gene targets for risperidone and clozapine, 
two commonly administered drugs for the treatment of schizophrenia. 
“Risperidone is a widely prescribed antipsychotic for the treatment 
of schizophrenia, with a relatively high rate of non-effectiveness or 
intolerable side effects” [18]. Due to the unwelcoming side effects, 
there is a high occurrence of risperidone non-compliance [18]. Some 
common examples of these side effects include “extrapyramidal 
symptoms (EPS), hyperprolactinemia, hyperlipidemia, weight gain, 
and metabolic syndrome” [18]. On the other hand, clozapine, compared 
to the other atypical antipsychotics, has been shown to be effective in 
30-60% of schizophrenia patients [6]. “Clozapine is the drug of choice 
for the management of treatment-resistant schizophrenia (TRS) 
because of its superior clinical efficacy, its ability to reduce suicidal 
risk, and its low propensity to produce movement disorders” [19]. 
In addition, since clozapine is able to interact with various serotonin 
and dopamine receptors, it is speculated to yield antipsychotic effects. 
However, the mechanisms are not yet clear [6]. Hence, knowledge and 
understanding of the behavior of specific genes that affect risperidone 
and clozapine treatment is of the utmost importance in order to guide 
the personalization of prescribing the optimal medication for each 
individual patient afflicted with schizophrenia [8]. 
The aim of this review is to understand genetic influences on 
drug responses in schizophrenia. To aid in the development of a 
pharmacogenetic test that would allow for the personalization of 
antipsychotic drugs in the hopes of reducing undesirable side effects [7]. 
Lastly, to provide an updated overview on risperidone and clozapine to 
guide physicians and clinical scientists in their clinical practice in order 
to reduce toxicity, increase efficacy and reduce the overall cost based on 
genotypes of each individual patient.
Methods
The primary aim of this review is to understand genetic influences 
on drug response in schizophrenia. There were a total of 52 publications 
with all five keywords (schizophrenia, pharmacogenetics, cytochrome 
P450, treatment, and psychiatric disorders (Figure 1). We then filtered 
for the Human species and the English language and identified a total of 
45 publications. After further filtering for free full text, 10 publications 
were identified. We assessed all 10 publications and identified 25 
candidate genes and selected eight of those candidate genes and 
their polymorphisms. The eight genes selected include Cytochrome 
P450 2D6 (CYP2D6), Catechol-O-methyltransferase (COMT), 
5-Hydroxytryptamine transporter (5HTT), 5-Hydroxytryptamine 
receptor 6 (5HT6), 5-Hydroxytryptamine receptor 2A (HTR2A), 
5-Hydroxytryptamine receptor 2C (HTR2C), Dopamine receptor 
D2 (DRD2) and Dopamine receptor D3 (DRD3). These genes were 
selected because they were the most prominent in our search in relation 
to clozapine and risperidone treatment.
Results
After filtering steps, we were focus on eight genes in association 
with antipsychotic treatment responses for patients with schizophrenia 
(Figure 1). 
CYP2D6 
The P450 enzyme system in the liver is the main system responsible 
for drug metabolism. CYP2D6, located on chromosome 22q13.1, is one 
of the major genes used by the system and it metabolizes around 20-25% 
of all clinically used medications, including risperidone and clozapine 
[20]. This gene is considered to be highly polymorphic. We discussed 
four genetic variants involved in differences in treatment responses in 
various populations (Table 1). Research shows that poor metabolizers 
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Records identified through the PubMed database search using keywords of schizophrenia, pharmacogenetics, 
cytochrome P450, treatment, and psychiatric disorders
(n=52)
↓
Additional filter for Human species and English language
(n=45)
↓
Additional filter for free full-text reviews asses for content selected as most relevant and recent
(n=10)
↓
25 candidate genes identified
↓
8 candidate genes selected
Figure 1: Workflow of publications used for this review paper.











•	 PMs tend to accumulate higher drug levels in blood, and theoretically, require 
lower doses to achieve therapeutic effects (Kakihara et al. [21], n=136; Riedel et 
al. [22], n=82)
•	 UMs may require higher doses of an antipsychotic due to faster elimination of the 






































•	 met/met genotype results in 3-4 fold lower enzyme activity compared with the val/
val allele pair (Zhang and Malhotra [20])
•	 met/val heterozygote results in intermediate enzyme activity (Zhang and Malhotra [20])
•	 val/val genotypes were less likely to respond to 8 weeks of clozapine treatment 














•	 Short allele is associated with poor response to clozapine and risperidone treatment 












•	 Significant association between the T/T genotype and better treatment response 













•	 Ca+2 mobilization ↓ (Zhang and Malhotra [20])
•	 Tyr variant is associated with reduced calcium release and reduced ability to 
activate phospholipases (Zhang and Malhotra [20])
•	 Tyr variant showed lowered antipsychotic binding affinity and ↓ drug potency 
(Arranz et al. [35], n=274; Masellis et al. [31], n=185; Arranz et al. [36], n=153)
•	 Tyr allele was significantly associated with poor response to clozapine treatment 
compared to the His allele (Arranz et al. [35], n=274; Masellis et al. [31], n=185; 











•	 C allele of T102C was more prevalent among non-responders for Clozapine 
(Arranz et al. [35], n=274)
•	 For risperidone response, there is a significant association between the C/C 










•	 G/G genotype was less likely to respond to clozapine (Arranz et al. [35], n=274, 










•	 Patients with Ser allele were more likely to respond to clozapine treatment 
compared to patients who are Cys/Cys homozygotes (n=162) Clozapine
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•	 Inhibition of cAMP synthesis ↓ (Itokawa et al. [50], n=50)














•	 Del allele carriers had poor response to clozapine (Malhotra et al. [43], n=72) and 
took longer time to respond to risperidone (Lencz et al. [44], n=61)
•	 Patients with the Ins/Ins genotype are 54% more likely to respond to antipsychotic 










•	 The A1 allele carriers were found to be more responsive to antipsychotic drugs 





















•	 In Asian samples, the A allele or A/A genotype was associated with better 
improvement after risperidone treatment (Xing et al. [51], n=125; Ikeda et al. [30], 
n=120) but took a long time to respond to risperidone in the American sample 










•	 The Gly 9 variant is associated with altered dopamine binding affinity and may ↑ 
DRD3 densities in some brain areas (Jeanneteau et al. [52], n=276)
Clozapine and 
Risperidone
A: African, C: Caucasian and/or European, E: European, H: Hispanic, As: Asian, N/A: Not Available, n: sample size, FGA: First Generation Antipsychotic, PM: Poor 
Metabolizer, IM: Intermediate Metabolizer, UM: Ultrarapid Metabolizer, EM: Extensive Metabolizer, Del: Deletion, Ins: Insertion 
Table 1: Genetic variation of eight genes involved in differences in treatment responses in various populations. 
(PMs) typically cause Risperidone build up in the blood. Thus, there is 
a lower dose requirement to attain a therapeutic effect for PMs [21,22]. 
In contrast, ultra rapid metabolizers (UMs) are needed in higher doses 
to produce a therapeutic effect [23]. Moreover, the (Table 1) also shows 
difference of allele frequencies of CYP2D6-3B (rs35742686) between 
the Caucasian (19%) and Africa and American population (2%) as 
well as CYP2D6-4 (rs3892097) between the Caucasian (24%) and 
Hispanic (6.5%) populations. Because of inter-ethnic heterogeneity, the 
dosage established in a landmark trial and clinical pharmacogenetics 
applications for a certain population may not be generalizable to other 
ethnic populations and a follow-up study is often needed to find the 
maximum tolerated dose for different populations. This problem even 
exists in various ethnic sub-populations [24].
5HTT
Actions of antipsychotic medications are believed to be significantly 
mediated by the serotonin system. Second generation antipsychotics 
bind to the 2A serotonin receptors relative to the D2 dopamine receptors. 
Therefore, different genetic variations have been studied in order to 
examine their associations to drug responses. The gene responsible 
for the serotonin transporter is known as 5HTT and is located on 
chromosome 17q11.2. This transporter, an integral membrane protein, 
allows for the entry of serotonin into presynaptic neurons. As a result, 
serotonin is recycled in a sodium-dependent method [20]. In three 
studies, one with a sample composed of 200 Caucasian participants 
[25], one with a sample of 129 Chinese participants [26] and one with 
a sample of 56 Caucasian participants [27], a deficient response was 
associated with the short allele for the 5-HTTLPR polymorphism 
for Clozapine and Risperidone treatment (Table 1). Again, there are 
different allele frequencies of the 5-HTTLPR polymorphism among the 
Africa American (22%), Caucasian (8.9%) and Asia (13%) populations. 
5HT6
Other variants of the serotonin system have been associated with 
drug efficacy, especially the 5HT6 gene. This gene codes for the 5HT6 
serotonin receptor [20]. Two studies, one with a sample composed of 
99 Chinese participants [28] and one with 123 Chinese participants 
[29] have shown a notable association among the T/T genotype and 
an improved response to Clozapine and Risperidone treatment in Han 
Chinese participants [28,29]. However, two other studies, one with 120 
Japanese participants [30] and one with 173 Caucasian and African 
American participants [31], did not show any association between the 
treatment response and genetic variance of the 5HT6 gene (Table 1). 
COMT
The COMT gene, located on chromosome 22q11.21, codes for 
the catechol-O-methyltransferase (COMT) enzyme. Antipsychotic 
drugs, such as Risperidone and Clozapine employ their effect on 
the dopaminergic pathways. Because COMT is one of the major 
enzymes responsible for dopamine clearance, it may be able to control 
antipsychotic action [20]. Research has shown that there is decreased 
enzyme activity by 3-4 folds in individuals expressing the met/met 
genotype as compared to the val/val genotype [20]. When treated with 
several first generation antipsychotics (FGAs), a case-control study 
with 94 Caucasian participants showed that the met/met genotype 
showed a decrease response to the treatment [32]. Furthermore, a 
study with 86 Caucasian and African American participants confirmed 
the previous findings and showed that individuals with the met allele 
were found to exhibit a response to Clozapine and positively influence 
cognitive functions [33]. Intermediate enzyme function is associated 
with individuals heterozygous for met/val genotype [20]. However, 
a study with a small sample size (59 Caucasian participants) showed 
that individuals with a val/val genotype undergoing an eight-week long 
treatment regimen were less likely to respond to Clozapine treatment 
[34] (Table 1). Therefore, future replication and confirmation need to 
valid these findings. In addition, the findings of COMT-Val108Met 
(rs4680) also demonstrate ethnic variability in treatment response 
phenotypes and different allele frequencies among three populations 
(Table 1). 
HTR2A
The gene HTR2A, located on chromosome 13q14-q21, codes for the 
5-HT 2A receptor. This receptor is usually found in the cerebral cortex 
and is often linked to the negative symptoms found in schizophrenia 
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patients. According to Zhang and Malhotra [20], the polymorphism 
His452Tyr is associated with a decrease in calcium mobilization, in 
calcium release, and in activation of phospholipases. In in-vitro data, 
the Tyr variant demonstrated a smaller drug binding affinity and 
lowered Clozapine and Risperidone potency. Unlike the His allele, the 
Tyr allele is correlated to a lowered response to Clozapine treatment in 
three studies with 153 Caucasian participants [35], 185 Caucasian and 
African American participants [31], and 274 Caucasian participants 
[36]. Similarly, in a meta-analysis with 274 Caucasian participants, the 
Tyr/Tyr genotype was correlated to a lowered response to Clozapine 
[35]. For the T102C (rs6313) polymorphism, there was a higher 
predominance of the C allele in non-responders undergoing Clozapine 
treatment [35]. For Risperidone treatment, individuals with the C/C 
genotype demonstrated an improved response in two studies with 100 
Chinese participants [37] and 100 Korean participants [38]. For the 
A-1438G (rs6311) polymorphism, individuals with the G/G genotype 
were shown to exhibit a decreased response to Clozapine treatment 
in two studies with 274 Caucasian participants [35] and 128 Chinese 
participants [39] (Table 1).
HTR2C
The gene HTR2C, located on chromosome Xq24, codes for the 
5-HT2C receptor. This receptor is usually found in the striatum, 
prefrontal cortex, and limbic system and it has a role in several 
pathways including memory, emotional processing, appetite, executive 
and motor functioning [20]. For the Cys23Ser polymorphism, a study 
with 162 Caucasian participants found that individuals with the Ser 
allele, unlike those who were homozygous for the Cys/Cys allele, had 
a higher rate of response to clozapine treatment [40]. However, three 
more recent studies one with 152 Caucasian participants [41], one with 
185 Caucasian and African American participants [31], and one with 
163 Caucasian participants [42] disagreed with this finding (Table 1). 
The current findings again suggest how complex and heterogeneity 
of genetics and treatment responses of clozapine among patients 
with schizophrenia. The contradictory findings might be due to the 
differences of the technique or genotype methods and the criteria to 
defined treatment responses used in different studies.  
DRD2
The gene DRD2, located on chromosome 11q22, codes for 
the dopamine D2 receptor [20]. In the -141C insertion/deletion 
polymorphism, carriers of the deletion allele exhibited an undesirable 
response to Clozapine in a study with 72 Caucasian and African 
American participants [43]. Furthermore, these carriers also exhibited 
a delayed response to Risperidone in a study with 61 Caucasian and 
African American participants [44]. On the other hand, individuals with 
the insertion/insertion genotype are more prone to exhibit a response 
to antipsychotic medication compared to individuals with one or more 
copies of the deletion allele in a meta-analysis with 687 participants 
[45]. The second polymorphism of the gene, the Taq1B polymorphism, 
particularly the T allele, has been linked to an increased response 
rate in African Americans in a study with 232 Caucasian and African 
American participants [46]. Carriers of the third polymorphism, 
Taq1A, showed a higher response to antipsychotic medications in three 
different studies, one with 25 Japanese participants [47], one with 57 
Caucasian participants [48] and one with 120 Japanese participants 
[30]. Individuals with the Ser311Cys polymorphism, the fourth 
polymorphism of the gene, specifically the Ser/Ser genotype, were 
prone to respond to Risperidone treatment in a study with 123 Chinese 
participants [49] and demonstrated a decrease in cAMP synthesis 
inhibition in a study with 50 Japanese participants [50]. For the A-241G 
polymorphism, Asian individuals with A allele or A/A genotype 
showed a positive improvement to Risperidone treatment in a study 
with 125 Chinese participants [51] and in study with 120 Japanese 
participants [30]. However, American individuals with the A allele or 
A/A genotype showed a delayed response to Risperidone treatment in a 
study with 61 Caucasian and African American participants [44]. Since 
these studies were conducted with different ethnic populations, slightly 
contradictory findings may be due to different allele frequencies of the 
markers in different ethnic populations (Table 1).
DRD3
The DRD3 gene, located on chromosome 3q13.3, codes for the D3 
dopamine receptor. This receptor is usually associated with the limbic 
system and basal ganglia. Because of its ability to inhibit spontaneous 
neurotransmitter transcription, this receptor plays a major role in 
neurotransmitter regulation [20]. For the Ser9Gly polymorphism, in 
the DRD3 gene, the Gly 9 variant was found to increase the affinity 
alteration of dopamine binding and seem to increase brain density in 
areas where DRD3 is found in individuals with this variant in a study 
with 30 French participants [52] (Table 1), however future study is 
needed to confirm these findings.
Discussion
Schizophrenia, a neuropsychiatric disorder, is known to 
be neurodevelopmentally progressive [1]. Due to the extensive 
interindividual variability found in the responses of patients, 
management of schizophrenia has proven to be challenging [3]. This 
interindividual variability to treatment could possibly be justified by 
the variation of the enzymes in charge of metabolizing medications, 
especially the enzyme system associated with cytochrome P450 
(CYP) [3]. Evidence exists for the critical role genetic factors play in 
antipsychotic medication treatment response. Decades of investigations 
and clinical studies are beginning to provide results that may soon be 
translated into clinical practice. We evaluated over 51 publications 
including reviews, meta-analyses, and original studies related to 
clozapine and risperidone antipsychotic treatment for schizophrenia and 
pharmacogenetics. We identified eight genes (CYP2D6, 5HTT, 5HT6, 
COMT, HTR2A, HTR2C, DRD2 and DRD3) with likely associations 
with treatment response that may be good candidates for translation 
into clinical applications of pharmacogenetics. Moreover, we focused 
on the frequency of genetic polymorphisms in specific populations 
such as Caucasian/European, African American, Hispanic and Asian. 
Both researchers in the field of pharmacogenetics and clinicians could 
benefit from a greater awareness of genetic polymorphisms associated 
with antipsychotic treatment response and their frequencies in different 
populations.
Finally, there is a paucity of pharmacogenetics antipsychotic studies 
in populations other than Caucasian and Asian. However, there is 
sufficient evidence demonstrating ethnic variability in antipsychotic 
response phenotypes with carriers of the identical polymorphisms 
in the genes we reviewed. We can conclude that this evidence points 
to polygenic influence with possible linkage disequilibrium affecting 
treatment outcomes. In order to elucidate the cause of ethnic variability, 
additional studies with diverse populations are needed and results 
should be stratified by ethnicity. The potential for pharmacogenetics 
to improve treatment outcomes in the realm of psychiatric diseases is 
undoubtedly vast. A greater focus on population specific outcomes may 
simplify the challenges remaining in the field.
Some of the major difficulties that we encountered for antipsychotic 
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pharmacogenetic studies were linked to small sample sizes, insufficient 
information on minority populations, and outdated studies on clozapine 
and risperidone despite the fact that they are widely prescribed 
antipsychotic medications for schizophrenia. Therefore, future 
directions should be aimed towards 1) studies including larger sample 
sizes, 2) studies including a larger sample of minority populations, such 
as the Hispanics and other minorities, 3) studies focused on clozapine 
and risperidone antipsychotic treatment response.
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